This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Gilead Sciences, Inc.. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Greg Cizio: Innovator in MCL1 Inhibitors
Introduction
Greg Cizio is a prominent inventor based in San Mateo, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of MCL1 inhibitors. With a total of 3 patents to his name, Cizio is recognized for his innovative approaches to drug development.
Latest Patents
Cizio's latest patents focus on processes and intermediates for preparing MCL1 inhibitors. The present disclosures provide methods for preparing MCL1 inhibitors or a salt thereof, along with related key intermediates. These advancements are crucial for the development of new therapeutic options in treating various diseases.
Career Highlights
Greg Cizio is currently employed at Gilead Sciences, Inc., a leading biopharmaceutical company. His work at Gilead has allowed him to collaborate with other talented professionals in the industry, further enhancing his contributions to pharmaceutical innovation.
Collaborations
Some of Cizio's notable coworkers include Katrien Brak and Kae M Bullock. Their collaborative efforts have played a significant role in advancing research and development within their field.
Conclusion
Greg Cizio's work in developing MCL1 inhibitors showcases his dedication to innovation in the pharmaceutical industry. His contributions are paving the way for new treatments and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile